Eleven Chinese healthcare and biotechnology companies filed applications to list on the Hong Kong stock exchange in the last two days of September, taking advantage of an ongoing investment boom in the sector. The best-known names among them are online healthcare services firm We Doctor Holdings, Sichuan Biokin Pharmaceutical – known for a US$8.4 billion licensing deal with US-based Bristol Myers Squibb (BMS) – and profitable cancer-drug developer Betta Pharmaceuticals. Other initial public...